IRIS
ANDREONI, MASSIMO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 75.357
EU - Europa 6.732
AS - Asia 3.557
SA - Sud America 74
OC - Oceania 42
AF - Africa 37
Continente sconosciuto - Info sul continente non disponibili 29
Totale 85.828
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 75.291
SG - Singapore 1.394
IT - Italia 1.316
DE - Germania 1.060
IE - Irlanda 1.045
UA - Ucraina 1.011
CN - Cina 943
KR - Corea 933
SE - Svezia 559
FR - Francia 385
GB - Regno Unito 369
PL - Polonia 263
FI - Finlandia 248
RU - Federazione Russa 220
BE - Belgio 89
CA - Canada 61
CZ - Repubblica Ceca 55
VN - Vietnam 52
BR - Brasile 43
IN - India 42
HK - Hong Kong 41
AU - Australia 39
JP - Giappone 34
NL - Olanda 32
KG - Kirghizistan 25
EU - Europa 21
CH - Svizzera 16
CL - Cile 16
TR - Turchia 16
ZA - Sudafrica 13
IR - Iran 12
PK - Pakistan 11
ES - Italia 10
GR - Grecia 10
IQ - Iraq 9
TW - Taiwan 9
A2 - ???statistics.table.value.countryCode.A2??? 8
RO - Romania 8
AR - Argentina 6
CO - Colombia 5
DK - Danimarca 5
ET - Etiopia 5
PH - Filippine 5
AT - Austria 4
IL - Israele 4
NO - Norvegia 4
SA - Arabia Saudita 4
AL - Albania 3
AM - Armenia 3
BA - Bosnia-Erzegovina 3
CM - Camerun 3
EG - Egitto 3
KZ - Kazakistan 3
LV - Lettonia 3
MD - Moldavia 3
MX - Messico 3
MY - Malesia 3
NG - Nigeria 3
NZ - Nuova Zelanda 3
TN - Tunisia 3
UG - Uganda 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
BD - Bangladesh 2
DM - Dominica 2
EC - Ecuador 2
ID - Indonesia 2
IS - Islanda 2
MN - Mongolia 2
PE - Perù 2
SK - Slovacchia (Repubblica Slovacca) 2
BG - Bulgaria 1
BJ - Benin 1
EE - Estonia 1
HR - Croazia 1
HU - Ungheria 1
LB - Libano 1
MA - Marocco 1
MK - Macedonia 1
NP - Nepal 1
PT - Portogallo 1
QA - Qatar 1
SC - Seychelles 1
TG - Togo 1
VA - Santa Sede (Città del Vaticano) 1
Totale 85.828
Salva come PNG Salva come JPEG
Città #
Woodbridge 21.755
Wilmington 21.509
Houston 15.667
Fairfield 2.592
Chandler 1.904
Ann Arbor 1.828
Ashburn 1.244
Singapore 1.180
Seattle 1.068
Cambridge 876
Dublin 871
Jacksonville 813
Medford 654
Dearborn 568
Rome 543
New York 452
Beijing 414
Lawrence 307
Santa Clara 294
Kraków 255
San Diego 201
Menlo Park 159
Milan 154
Moscow 132
Zhengzhou 126
Mülheim 99
Boardman 91
Brussels 88
London 59
Palo Alto 57
Nanjing 55
Helsinki 53
Falls Church 50
Redwood City 47
Norwalk 44
Dong Ket 43
San Mateo 42
Hefei 41
Creede 40
Hangzhou 40
Brno 38
Guangzhou 38
Munich 38
Mountain View 37
Seoul 36
Phoenix 35
Toronto 35
Verona 35
Hong Kong 33
Shanghai 33
Kunming 32
University Park 28
San Francisco 27
Los Angeles 22
São Paulo 20
Engelhard 19
Jinan 19
Naples 19
Saint Petersburg 19
Nuremberg 18
Wuhan 18
Olomouc 17
Redmond 17
Cedarhurst 16
Kilburn 16
Adelaide 15
Amsterdam 15
Roebling 15
Tokyo 15
Nanchang 14
San Jose 14
Colorado Springs 13
Council Bluffs 13
Ottawa 13
Auburn Hills 12
Chengdu 12
Nürnberg 12
Bari 11
Hounslow 11
Palermo 11
Indiana 10
La Veta 10
Prescot 10
Turin 10
Washington 10
Fuzhou 9
Hebei 9
Atlanta 8
Durham 8
Latina 8
Shenyang 8
Clearwater 7
Hanoi 7
Lappeenranta 7
Sydney 7
Umuarama 7
Detroit 6
Modena 6
Monte Vista 6
Oakland 6
Totale 77.435
Salva come PNG Salva come JPEG
Nome #
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 505
Persistent risk of HBV reactivation despite extensive lamivudine prophylaxis in haematopoietic stem cell transplant recipients who are anti-HBc-positive or HBV-negative recipients with an anti-HBc-positive donor 493
The Genotypic False Positive Rate Determined by Population V3-Sequencing can Predict the Burden of X4 Quasispecies Detected by Pyrosequencing 489
Microbiologic characteristics and predictors of mortality in bloodstream infections in intensive care unit patients: A 1-year, large, prospective surveillance study in 5 Italian hospitals 478
Human herpesvirus-8 infection in pregnancy and labor: Lack of evidence of vertical transmission 447
Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy 446
Cellular HIV-1 DNA quantitation in patients during simplification therapy with protease inhibitor-sparing regimens 446
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice 445
Hepatitis B surface antigen genetic elements critical for immune escape correlate with hepatitis B virus reactivation upon immunosuppression 441
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 441
Drug-associated resistance mutations in plasma and peripheral blood mononuclear cells of human immunodeficiency virus type 1-infected patients for whom highly active antiretroviral therapy is failing 438
Prognostic factors of long-term CD4+ count-guided interruption of antiretroviral treatment 433
Specific mutations in the C-terminus domain of HBV surface antigen significantly correlate with low level of serum HBV-DNA in patients with chronic HBV infection 432
18-Fluoro-2-deoxyglucose positron emission tomography-computed tomography: an additional tool in the diagnosis of prosthetic valve endocarditis. 431
Novel HBsAg mutations correlate with hepatocellular carcinoma, hamper HBsAg secretion and promote cell proliferation in vitro 426
Clinical predictors and microbiology of ventilator-associated pneumonia in the intensive care unit: a retrospective analysis in six Italian hospitals 426
Viro-immunological response of drug-naive HIV-1-infected patients starting a first-line regimen with viraemia >500,000 copies/ml in clinical practice 426
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance. 425
A stable CC-chemokine receptor (CCR)-5 tropic virus is correlated with the persistence of HIV RNA at less than 2.5 copies in successfully treated naïve subjects. 420
Hepatitis C virus RNA levels at week-2 of telaprevir/boceprevir administration are predictive of virological outcome 419
HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (< 400 HIV-RNA cp/ml) during different antiretroviral regimens 418
Infection with human herpesvirus type 8 and Kaposi's sarcoma in a central Italian area formerly endemic for malaria 414
Efficient and reproducible new semimicromethod for the detection and titration of HIV in human plasma 413
Association between cellular human immunodeficiency virus DNA level and immunological parameters in patients with undetectable plasma viremia level during highly active antiretroviral therapy 412
Novel HBsAg markers tightly correlate with occult HBV infection and strongly affect HBsAg detection. 411
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 408
Specific HbsAg genetic determinants are associated with occult HBV infection in vivo and HbsAg detection 407
Drug resistance in B and non-B subtypes amongst subjects recently diagnosed as primary/recent or chronic HIV-infected over the period 2013-2016: impact on susceptibility to first-line strategies including Integrase strand-transfer inhibitors 407
Neutralizing antibodies against autologous human immunodeficiency virus type 1 isolates in patients with increasing CD4 cell counts despite incomplete virus suppression during antiretroviral treatment 405
HIV plasma viremia in 22 seropositive subjects [VALUTAZIONE DELLA VIREMIA PLASMATICA DA HIV IN 22 SOGGETTI SIERO-POSITIVI] 405
Failure of stavudine-lamivudine combination therapy in antiretroviral-naive patients with AZT-like HIV-1 resistance mutations 405
High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis 405
Reduction of IFN-gamma and IL-2 production by peripheral lymphocytes of HIV-exposed seronegative subjects 403
High seroprevalence of antibodies to human herpesvirus-8 in Egyptian children: evidence of nonsexual transmission. 403
Cortical sources of resting state electroencephalographic rhythms probe brain function in naïve HIV individuals 401
Infection with human herpesvirus-8 and its correlation with hepatitis B virus and hepatitis C virus markers among rural populations in Cambodia 400
A fatal case of invasive fungal sinusitis by Scopulariopsis acremonium in a bone marrow transplant recipient 400
Comparative evaluation of subtyping tools for the surveillance of newly emerging HIV-1 strains 400
Interleukin-15 production by monocyte-derived dendritic cells and T cell proliferation in HIV-infected patients with discordant response to highly active antiretroviral therapy 399
HCV genotypes are differently prone to the development of resistance to linear and macrocyclic protease inhibitors 399
Specific HBSAG Genetic- Determinants are associated with occult HBV-infection in vivo and HBSAG detection 399
Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration 398
Multidrug resistance after lamivudine therapy for chronic hepatitis B 396
Human herpesvirus 8 and human herpesvirus 2 infections in prison population 395
Clinical outcome after 4 years follow-up of HIV-seropositive subjects with incomplete virologic or immunologic response to HAART 393
Prevalence of HHV-8 infection in Albanian adults and association with HBV and HCV 392
Prevalence and risk factors for human herpesvirus 8 infection in northern Cameroon 392
Identification and structural characterization of novel genetic elements in the HIV-1 V3 loop regulating coreceptor usage 391
HIV phenotype switching during antiretroviral therapy: emergence of saquinavir-resistant strains with less cytopathogenicity 391
Primary human herpesvirus 8 infection in immunocompetent children. 391
Human herpesvirus 8 cytoviraemia rebound in a patient with Kaposi's sarcoma after a short interruption of efficient antiretroviral therapy. 390
Decrease of replicative capacity of HIV isolates after genotypic guided change of therapy 388
Plasma Viremia Titration and RNA Quantitation in ICD-p24 Negative HIV Type-1-Infected Patients 388
Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens 388
Correlation between changes in plasma HIV RNA levels and in plasma infectivity in response to antiretroviral therapy. 387
Optimal efficacy of interferon-free HCV retreatment after protease inhibitors failure in real life. 386
Prevalence trend and correlates of HHV-8 infection in HIV-infected patients 385
The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients 383
A case of rhabdomiolysis associated with raltegravir use 382
Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: A cross-sectional evaluation 380
KSHV DNA viremia correlates with low CD4+ cell count in Italian males at the time of diagnosis of HIV infection 380
Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation 380
Five human immunodeficiency virus type 1 phenotypic variants with different MT-2 cell tropisms correlate with prognostic markers of disease 380
Once-a-day (QD) vs. Twice-daily (BID) Nevirapine as Simplification in PI-Treated Patients after 2 mos. of BID Induction 379
Procalcitonin is a reliable marker of severe systemic infection in neutropenic haematological patients with mucositis 378
Key patterns of HBX and pre-S1/S2 mutations are involved in mechanisms underlying HBV-induced hepatocellular carcinoma in vivo 378
Correlates of HIV, HBV, and HCV infections in a prison inmate population: Results from a multicentre study in Italy 377
Viral growth assay to evaluate the replicative capacity of HIV-1 isolates 377
Infection with human herpesvirus type 8 and human T-cell leukaemia virus type 1 among individuals participating in a case-control study in Havana City, Cuba 376
Successful switch to tenofovir after suboptimal response to entecavir in an immunocompromised patient with chronic hepatitis B and without genotypic hepatitis B virus resistance 376
ellular proviral HIV-DNA decline and viral isolation in naïve subjects with <5000 copies/ml of HIV-RNA and >500 x 10(6)/l CD4 cells treated with highly active antiretroviral therapy. 376
Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group 375
Biomarkers of monitoring and functional reserve of physiological systems over time in HIV: expert opinions for effective secondary prevention 375
Dapsone hypersensitivity syndrome complicated by Scedosporium apiospermum pneumonia in an immunocompetent patient. 374
Reply to 'Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides', by Barreiro et al. [2] 373
Increase in neutralizing antibody titer against sequential autologous HIV-1 isolates after 16 weeks saquinavir (invirase) treatment 370
Snapshot on drug-resistance rate and profiles in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. 370
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 369
Saquinavir delays the emergence of zidovudine resistance in HIV-1 seropositive patients treated with combination therapy. 369
Efficacy of cidofovir on human herpesvirus 8 viraemia and Kaposi's sarcoma progression in two patients with AIDS [1] 368
Time course of cellular HIV-DNA and low-level HIV viremia in HIV–HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals 368
Genotypic resistance test in proviral DNA can identify resistance mutations never detected in historical genotypic test in patients with low level or undetectable HIV-RNA 368
HBV, HCV, HDV AND HEV COINFECTIONS IN A COHORT OF HIV POSITIVE PATIENTS IN CAMEROON 366
Anti-HBV treatment induces novel reverse transcriptase mutations with reflective effect on HBV S antigen 366
Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation 365
Reliability and clinical relevance of the HIV-1 drug resistance test in patients with low viremia levels 365
Stavudine protective function and emergence of lamivudine resistance [4] (multiple letters) 365
Adherence and genotypic drug resistance mutations in HIV-1-infected patients failing current antiretroviral therapy 364
Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy 363
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group 363
HIV-1 integrase genotyping is reliable and reproducible for routine clinical detection of integrase resistance mutations even in patients with low-level viraemia 363
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens 363
Non-B HIV type 1 subtypes: Replicative capacity and response to antiretroviral therapy 362
Optimal cure rate by personalized HCV regimens in real-life: a proof-of-concept study 362
Complication of nasal piercing by Staphylococcus aureus endocarditis: a case report and a review of literature. 361
Infection with human immunodeficiency virus, herpes simplex virus type 2, and human herpes virus 8 in remote villages of southwestern Papua New Guinea 360
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors 359
Development of cellulitis caused by Aeromonas hydrophila in allogeneic hematopoietic transplantation: a case report. 359
Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity. 359
High rate of HIV isolation from plasma of asymptomatic patients through polyethylene glycol (PEG) treatment 358
Totale 39.576
Salva come PNG Salva come JPEG
Categoria #
all - tutte 185.323
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 185.323
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202018.503 0 0 1.522 2.014 1.987 2.482 2.153 1.894 1.876 1.835 1.320 1.420
2020/202112.797 1.494 1.348 1.383 1.639 1.166 1.434 1.697 1.234 298 351 505 248
2021/20224.030 182 314 229 272 173 449 225 225 480 316 243 922
2022/20235.071 491 417 304 654 431 1.056 380 407 477 40 275 139
2023/20242.150 269 79 165 113 170 471 105 149 56 146 32 395
2024/20252.260 331 1.908 21 0 0 0 0 0 0 0 0 0
Totale 86.999